



OPEN ACCESS

**Edited by:**

Maria Olivia Pereira,  
University of Minho, Portugal

**Reviewed by:**

Rodolfo García-Contreras,  
Universidad Nacional Autónoma  
de México, Mexico  
Vishvanath Tiwari,  
Central University of Rajasthan, India  
Paul Cos,  
University of Antwerp, Belgium

**\*Correspondence:**

Jan Michiels  
jan.michiels@kuleuven.vib.be

**†Present address:**

Romu Corbau,  
Freeline Therapeutics, UCL Royal  
Free Medical School, London,  
United Kingdom

‡These authors are joint senior  
authors.

**Specialty section:**

This article was submitted to  
Antimicrobials, Resistance  
and Chemotherapy,  
a section of the journal  
Frontiers in Microbiology

**Received:** 07 August 2017

**Accepted:** 12 December 2017

**Published:** 22 December 2017

**Citation:**

Defraigne V, Verstraete L,  
Van Bambeke F, Anantharajah A,  
Townsend EM, Ramage G,  
Corbau R, Marchand A, Chaltin P,  
Fauvart M and Michiels J (2017)  
Antibacterial Activity  
of 1-[(2,4-Dichlorophenethyl)amino]-  
3-Phenoxypropan-2-ol against  
Antibiotic-Resistant Strains of Diverse  
Bacterial Pathogens, Biofilms  
and in Pre-clinical Infection Models.  
Front. Microbiol. 8:2585.  
doi: 10.3389/fmicb.2017.02585

# Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3- Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models

Valerie Defraigne<sup>1,2</sup>, Laure Verstraete<sup>1,2</sup>, Françoise Van Bambeke<sup>3</sup>,  
Ahalieyah Anantharajah<sup>3</sup>, Eleanor M. Townsend<sup>4,5</sup>, Gordon Ramage<sup>4</sup>, Romu Corbau<sup>6†</sup>,  
Arnaud Marchand<sup>6</sup>, Patrick Chaltin<sup>6,7</sup>, Maarten Fauvart<sup>1,8‡</sup> and Jan Michiels<sup>1,2\*‡</sup>

<sup>1</sup> Centre of Microbial and Plant Genetics, University of Leuven, Leuven, Belgium, <sup>2</sup> Center for Microbiology, Vlaams Instituut voor Biotechnologie, Leuven, Belgium, <sup>3</sup> Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium, <sup>4</sup> Oral Science Research Group, Glasgow Dental School, University of Glasgow, Glasgow, United Kingdom, <sup>5</sup> Institute of Healthcare Policy and Practice, University of West of Scotland, Paisley, United Kingdom, <sup>6</sup> CISTIM Leuven vzw, Leuven, Belgium, <sup>7</sup> Centre for Drug Design and Discovery, Leuven, Belgium, <sup>8</sup> Department of Life Sciences and Imaging, Smart Electronics Unit, imec, Leuven, Belgium

We recently described the novel anti-persister compound 1-[(2,4-dichlorophenethyl)amino]-3-phenoxypropan-2-ol (SPI009), capable of directly killing persister cells of the Gram-negative pathogen *Pseudomonas aeruginosa*. This compound also shows antibacterial effects against non-persister cells, suggesting that SPI009 could be used as an adjuvant for antibacterial combination therapy. Here, we demonstrate the broad-spectrum activity of SPI009, combined with different classes of antibiotics, against the clinically relevant ESKAPE pathogens *Enterobacter aerogenes*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, *Enterococcus faecium* and *Burkholderia cenocepacia* and *Escherichia coli*. Importantly, SPI009 re-enabled killing of antibiotic-resistant strains and effectively lowered the required antibiotic concentrations. The clinical potential was further confirmed in biofilm models of *P. aeruginosa* and *S. aureus* where SPI009 exhibited effective biofilm inhibition and eradication. *Caenorhabditis elegans* infected with *P. aeruginosa* also showed a significant improvement in survival when SPI009 was added to conventional antibiotic treatment. Overall, we demonstrate that SPI009, initially discovered as an anti-persister molecule in *P. aeruginosa*, possesses broad-spectrum activity and is highly suitable for the development of antibacterial combination therapies in the fight against chronic infections.

**Keywords:** antibacterials, *P. aeruginosa*, ESKAPE pathogens, anti-persister therapies, antibiotic resistance

## INTRODUCTION

Antibiotic resistance is rapidly increasing in the majority of nosocomial pathogens, complicating the effective treatment of bacterial infections and transforming once easily cured diseases into serious human health threats (European Centre for Disease Prevention and Control, 2013; O'Neill, 2016). Although selection for resistance in microorganisms is inevitable, the widespread and excessive use of antibiotics allowed pathogens to efficiently adapt to these stressful conditions, resulting in the occurrence of extensively drug-resistant and pan-drug resistant strains (Livermore, 2004; Fischbach and Walsh, 2009). In an attempt to guide research and development toward the most critical pathogens, the World Health Organization (WHO) recently published their 'global priority list,' containing 12 bacterial pathogens that raise particular concern (WHO, 2017). Among these are the so-called ESKAPE pathogens, *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, and *Enterobacter* spp., which efficiently evade antibiotic treatment and represent new paradigms in pathogenesis, transmission, and resistance (Rice, 2008). Together, this select group of bacteria is responsible for most of the hospital-acquired infections and, despite increasing research efforts, therapeutic options remain scarce (Bassetti et al., 2013; Pendleton et al., 2013). Greatly contributing to the difficult treatment of these bacterial infections is the presence of non-growing persister cells. These phenotypic variants show a reduced metabolic activity, are able to withstand intensive antibiotic treatment, and when antibiotic pressure drops, are capable of restoring the bacterial population, causing recurrence of infection (Fauvart et al., 2011; Van den Bergh et al., 2017). Persistence is widely acknowledged as a major culprit of treatment failure in chronic and biofilm infections and recent research has identified the persister fraction as a possible reservoir for the development of resistance (Lewis, 2007; Cohen et al., 2013). Effective elimination of persister cells could significantly improve patient outcomes, but their small numbers and the apparent redundancy in persister mechanisms greatly hampers the development of targeted anti-persister therapies.

We recently reported the identification of a novel anti-persister molecule capable of directly killing persister cells of *P. aeruginosa* (Liebens et al., 2017). SPI009 was identified in a screening of 23,909 small molecules for compounds that decrease the persister fraction of *P. aeruginosa* in combination with the conventional antibiotic ofloxacin. In the present study, we explore the activity of SPI009 in several additional pathogens and demonstrate broad spectrum activity and the ability to sensitize resistant strains. Furthermore, SPI009 was shown to retain activity in different biofilm models and is capable of significantly improving antibiotic efficacy both in *in vitro* and *in vivo* infection models. Overall, these results further increase the clinical potential of SPI009 and offer compelling perspectives for the use of SPI009 as an adjuvant in effective antimicrobial therapies.

## MATERIALS AND METHODS

### Bacterial Strains, Human Cell Lines, *C. elegans*, and Culture Conditions

Bacterial strains used in this study are listed in Table 1. All strains were cultured in 1:20 diluted Trypticase Soy Broth (1/20 TSB) at 37°C shaking at 200 rpm. For solid medium, TSB was supplemented with 1.5% agar. Human THP-1 cell lines were cultivated in RPMI-1640 medium containing 10% fetal calf serum at 37°C with 5% CO<sub>2</sub>. The *C. elegans* AU37 strain [*glp-4(bn2); sek-1(km4)*] was obtained from the Caenorhabditis Genetics Center (CGC) and maintained according to standards (Stiernagle, 2006). The following antibacterials were used: ofloxacin, ciprofloxacin, rifampicin, polymyxin B, vancomycin (Sigma-Aldrich), and 1-[(2,4-dichlorophenethyl)amino]-3-phenoxypropan-2-ol (SPI009; CD3) with concentrations indicated throughout the text.

### Antibacterial Assays

Antibacterial assays were performed on different clinically relevant pathogens as previously described (Liebens et al., 2017). Briefly, stationary phase cultures were treated for 5 h with 17 or 34 µg/mL of SPI009 alone or in combination with an appropriate antibiotic to assess anti-bacterial and anti-persister effects, respectively. To evaluate activity against resistant strains, stationary phase cultures were treated for 5 h with 1x, 4x, and 8x MIC concentrations of the respective antibiotic; 17 or 34 µg/mL SPI009 or the combination of both. After treatment, cells were washed and viability was assessed via plating.

### Quantification of Biofilm Formation and Eradication after Treatment with SPI009

Overnight cultures of *P. aeruginosa* PA14 WT or *S. aureus* ATCC 33591 were diluted 1:100 in 1/20 TSB medium supplemented with 2% DMSO (carrier control) or increasing concentrations of SPI009 (4.25–68 µg/mL). Biofilms were grown for 24 h at 37°C on the bottom of a polystyrene 96-well plate, non-shaking. Medium and free-living cells were removed and the biofilms were washed, scraped off and passed five times through a syringe (0.5 mm × 1.6 mm) to disrupt any cell clumps and obtain single cells (Hermans et al., 2011). Appropriate dilutions made in 1x PBS were plated on solid TSB agar plates to assess biofilm growth under different conditions.

To explore the biofilm eradicating effects of SPI009, overnight cultures of *P. aeruginosa* PA14 WT or *S. aureus* ATCC 33591 were diluted 1:100 in 1/20 TSB medium and incubated for 24 h at 37°C (non-shaking). Mature biofilms were treated for 5 h with 2% DMSO and increasing concentrations of SPI009 (8.5–136 µg/mL) at 37°C, non-shaking, after which the remaining biofilms were processed as described above.

### Chronic Wound Model

A three-dimensional wound biofilm model was used, as previously described (Townsend et al., 2016). *P. aeruginosa* coated cellulose matrices, obtained after 2 h of adhesion ( $1 \times 10^6$

**TABLE 1 |** Strains used in this study.

| Strain                          | Description                                                                                                                                                                                                                    | Source or reference                                |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| <i>P. aeruginosa</i> PA14       | Wild type; UBCPP-PA14                                                                                                                                                                                                          | Pierre Cornelis; Lee et al., 2006                  |
| <i>P. aeruginosa</i> PAO1       | Wild type                                                                                                                                                                                                                      | Dieter Haas (ETH)                                  |
| <i>P. aeruginosa</i> PA62       | Broncho-pulmonary clinical isolate OFX <sup>R</sup> , CIP <sup>R</sup> , GEN <sup>R</sup> , AMK <sup>R</sup> , ATM <sup>R</sup> , TIC <sup>R</sup> , PIP <sup>R</sup> , TZP <sup>R</sup> , CAZ <sup>R</sup> , FEP <sup>R</sup> | Françoise van Bambeke (UCL)                        |
| <i>P. aeruginosa</i> 9BR        | Clinical isolate, PBM <sup>R</sup> , MEM <sup>R</sup> , CIP <sup>R</sup> , and FEP <sup>R</sup> , CAZ <sup>R</sup> , or TZP <sup>R</sup>                                                                                       | Bob Hancock; Boyle et al., 2012                    |
| <i>E. aerogenes</i>             | ATCC 13048 (KCTC 2190)                                                                                                                                                                                                         | Shin et al., 2012                                  |
| <i>S. aureus</i> Rosenbach 1844 | Wild type, methicillin resistant, ATCC 33591                                                                                                                                                                                   | BCCM/LGM bacterial collection; Conlon et al., 2013 |
| <i>K. pneumoniae</i>            | ATCC 13883                                                                                                                                                                                                                     | Arivett et al., 2015                               |
| <i>A. baumannii</i>             | RUH134                                                                                                                                                                                                                         | Jean-Paul Pirnay; Merabishvili et al., 2014        |
| <i>E. faecium</i>               | LMG 8148                                                                                                                                                                                                                       | Descheemaeker et al., 1997                         |
| <i>B. cenocepacia</i> K56-2     | LMG 18863                                                                                                                                                                                                                      | Van Acker et al., 2013                             |
| <i>E. coli</i> BW25113          | F <sup>-</sup> , Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ <sup>-</sup> , rph-1, Δ(rhaD-rhaB)568, hsdR514                                                                                                                        | Baba et al., 2006                                  |

Resistance profiles determined according to EUCAST MIC breakpoints (European Committee on Antimicrobial Susceptibility Testing, 2017). OFX, ofloxacin; CIP, ciprofloxacin; GEN, gentamicin; AMK, amikacin; ATM, aztreonam; TIC, ticarcillin; PIP, piperacillin; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; PBM, polymyxin B; MEM, meropenem.

cells/mL), were placed onto the hydrogels after which 3D biofilm development was allowed for 24 h at 37°C. Mature biofilms were treated for 24 h with DMSO (1%), 10 µg/mL ofloxacin, 34 and 69 µg/mL of SPI009 or the combination of ofloxacin and SPI009. Any non-adherent cells were removed by rinsing after which biomass was removed by sonication at 35 kHz for 10 min and DNA was extracted. Samples were prepared as previously described and viability-based qPCR using *P. aeruginosa* specific primers F- GGGCGAAGAAGGAAATGGTC and R- CAGGTGGCGTAGGTGGAGAA was used to determine live and total fractions of biofilm cells under different treatment conditions (Smith et al., 2016). Standard curves were used to convert the obtained qPCR values to colony forming estimates (CFEs), after which log<sub>10</sub>-transformed values were used for statistical analysis, as described below. All experiments were carried out in triplicate, each containing three technical repeats.

## Intracellular Infection Model

Infection of human THP-1 cells was performed as described previously, with minor modifications (Buyck et al., 2013). Since a newly synthesized batch of SPI009 was used for this experiment, cytotoxicity assessment via an LDH enzyme assay was repeated for the THP-1 cell line, as previously described (Liebens et al., 2017). After THP-1 infection with *P. aeruginosa* PAO1 and subsequent removal of any non-phagocytosed or adherent bacteria, ciprofloxacin and SPI009 were added in final concentrations of, respectively, 0–20 µg/mL and 6.8 or 10.2 µg/mL. After 5 h of treatment, eukaryotic cells were collected in three consecutive centrifugation steps and complete cell lysis was obtained by sonication (10 s). Lysates were used for bacterial CFU counting and determination of protein content by Lowry's assay (Bio-Rad DC protein assay kit; Bio-Rad laboratories, Hercules, CA, United States). For analysis of surviving bacterial cells, CFU data were divided by corresponding protein content for normalization.

## *C. elegans* Toxicity Testing and Survival Assay

AU37 nematodes were synchronized as previously described (Porta-de-la-Riva et al., 2012) to obtain L4 worms suitable for toxicity and infection assays (Briers et al., 2014). Larvae obtained after bleaching were plated onto solid NGM-OP50 agar plates and incubated at 25°C during 2 days to allow development of the worms to the L4 stage. Worms were transferred to fresh NGM agar plates containing OP50 (toxicity testing and uninfected control) or PA14 (infection) for an additional 24 h at 25°C.

To evaluate toxicity of SPI009 L4 nematodes grown on OP50 were transferred to 12-well plates (20–30 worms/well) containing different concentrations of SPI009 (8.5–136 µg/mL) in 1.5 mL NGM:M9 (1:4). Controls consisted of untreated worms and DMSO (2% and 20%). For the infection assay, adult worms were allowed to feed on NGM-PA14 plates for 24 h, after which residual bacteria were removed and nematodes were divided over a 12-well plate (20–30 worms/well). Different treatments were prepared in 1.5 mL NGM:M9 (1:4) and consisted of an untreated control, 1.56 µg/mL ciprofloxacin (5x MIC), 8.5 µg/mL of SPI009 and the combination of ciprofloxacin and SPI009. As an additional control, uninfected worms were included. For both assays, worms were incubated at 25°C and survival was scored visually for 6 days.

## Statistical Analysis

Unless mentioned otherwise, all statistical analyses were performed on log<sub>10</sub>-transformed data using GraphPad Prism software (version 6.01). Bacterial survival after different treatments was compared to the untreated or antibiotic control using a one-way ANOVA ( $\alpha = 0.05$ ), with Dunnett's correction for multiple comparisons. Statistical comparison of mono- and combination treatment in resistant strains was done using a two-way ANOVA ( $\alpha = 0.05$ ) with Tukey correction for multiple comparisons. Statistical analysis of the *in vivo C. elegans* data was done by means of a log-rank test using GraphPad Prism.

## RESULTS


### SPI009 Shows Broad-Spectrum Activity against Different Clinically Relevant Bacterial Species


The activity of SPI009 was previously assessed in *P. aeruginosa* PA14 and several clinical isolates where combination with ofloxacin significantly decreased the persister fraction in all strains tested (Liebens et al., 2017). In the present study, we challenged a panel of clinically relevant species, including the ESKAPE pathogens (Figure 1A), *B. cenocepacia* and *E. coli* (Figure 1B). For each species appropriate concentrations of a conventional antibiotic used in the clinic were selected to allow only persister cells to survive (Supplementary Figure S1). Combination of the antibiotic with 17  $\mu\text{g/mL}$  SPI009 significantly decreased the number of surviving bacteria for five of the eight species with reductions in CFU ranging between  $1.5 \pm 0.1$  and  $6.0 \pm 0.2$  log units and complete eradication of *K. pneumoniae*. Addition of 34  $\mu\text{g/mL}$  completely eradicated the bacterial cultures of five of the eight species tested and resulted in significant  $6.6 \pm 0.5$  log,  $6.2 \pm 1.3$  log, and  $5.4 \pm 0.5$  log reductions in bacterial survival for *S. aureus*, *E. faecium*, and *B. cenocepacia*, respectively. No reduction in survival is observed after treatment with 17  $\mu\text{g/mL}$  for either of the Gram-positive species, *E. faecium* and *S. aureus*. These results suggest that the latter two species, and the Gram-negative *B. cenocepacia*, are slightly less sensitive toward the combination therapy. *K. pneumoniae* proved the most susceptible species toward SPI009. Overall, the obtained results further support the antibacterial effect of SPI009 and reveal a broad-spectrum activity.

### SPI009 Sensitizes Antibiotic-Resistant Strains


To investigate the possible use of SPI009 as an adjuvant in antibacterial combination therapies, several (multi)drug-resistant strains were treated with 1x, 4x, and 8x MIC concentrations of the antibiotic, alone and in combination with SPI009. While SPI009 alone did not cause a significant decrease in survival of the ofloxacin resistant *P. aeruginosa* PA62, addition of 17 or 34  $\mu\text{g/mL}$  of SPI009 significantly reduced the number of surviving cells by  $5.3 \pm 0.9$  and  $7.8 \pm 0.9$  log units at 4x MIC of ofloxacin while combination with 8x MIC completely eradicated the bacterial culture (Figure 2A). In comparison, treatment with ofloxacin alone caused  $0.8 \pm 0.9$  log and  $2.8 \pm 0.9$  log decreases in surviving cells at concentrations of 4x MIC and 8x MIC, respectively.

A similar trend was observed in the polymyxin B resistant *P. aeruginosa* 9BR (Figure 2B). Here, addition of the antibiotic alone had a slightly greater effect but combination with SPI009 still significantly improved the treatment and 17  $\mu\text{g/mL}$  of SPI009 successfully eradicated the entire bacterial culture in combination with 4x MIC of polymyxin B. A somewhat smaller effect was observed in the polymyxin B resistant *B. cenocepacia* strain K56-2, for which addition of 17  $\mu\text{g/mL}$  and 34  $\mu\text{g/mL}$  SPI009 to 4x MIC polymyxin B resulted in significant  $4.9 \pm 0.5$  and





**FIGURE 2 |** SPI009 re-enables the treatment of (multi)drug-resistant strains. Stationary phase cultures of (A) *P. aeruginosa* PA62 (OFX<sup>R</sup>), (B) *P. aeruginosa* 9BR (PMB<sup>R</sup>) and (C) *B. cenocepacia* K56-2 (PMB<sup>R</sup>) were treated for 5 h with 1x MIC, 4x MIC, and 8x MIC concentrations of the respective antibiotic alone and in combination with 17 or 34 µg/mL of SPI009. Data points represent the average of at least three biological repeats. SEM values are shown as error bars. Statistical analysis was done by means of two-way ANOVA ( $\alpha = 0.05$ ) with Tukey correction for multiple comparisons and  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.001$ ,  $****P \leq 0.0001$ ; ND, not detected.



**FIGURE 3 |** Anti-biofilm effects of SPI009 in *P. aeruginosa* and *S. aureus*. Increasing concentrations of SPI009 (4.25–136 µg/mL) and a DMSO control were added for (A) 24 h to 1:100 diluted cultures or (B) 5 h to 24-h-old biofilms in 96-well microtiter plates to assess biofilm inhibition and eradication, respectively. After treatment, biofilms were washed, disturbed and plated out to calculate the number of surviving cells. Data points represent the percentage of surviving cells relative to the untreated control as an average of at least three biological repeats, each containing three technical repeats. Error bars depict SEM values. Statistical significance was calculated on  $\log_{10}$  transformed CFU counts using a one-way ANOVA with Dunnett's correction for multiple comparisons.  $*P \leq 0.05$ ,  $**P \leq 0.01$ ,  $***P \leq 0.001$ ,  $****P \leq 0.0001$ . ND, not detectable.

$5.2 \pm 0.5$  log decreases in survival. Combinations with higher concentrations of polymyxin B (8x MIC) did not further decrease the number of surviving cells (Figure 2C). The obtained results

clearly demonstrate the effective use of SPI009 as an adjuvant for antibacterial therapy thereby facilitating the treatment of different antibiotic-resistant strains. Furthermore, SPI009 retains

activity in multidrug-resistant strains, revealing the lack of cross-resistance. Importantly, resensitization of resistant strains could restore the effectiveness of established antibiotics.


## Biofilm Inhibition and Eradication Effects of SPI009

To assess biofilm inhibiting properties of SPI009 in *P. aeruginosa* and *S. aureus*, biofilm growth was allowed in the presence of increasing concentrations of SPI009 (Figure 3A). Analysis of the obtained results clearly show an effective inhibition of biofilm growth in both *P. aeruginosa* and *S. aureus*. For *P. aeruginosa*, a steep increase in inhibitory activity was observed at concentrations above 8.5  $\mu\text{g/mL}$ , resulting in  $1.8 \pm 0.5$  log and  $2.4 \pm 0.4$  log decreases at 17 or 34  $\mu\text{g/mL}$  SPI009, respectively, and complete inhibition of biofilm growth at 68  $\mu\text{g/mL}$ . *S. aureus* showed a more gradual decrease in biofilm formation with 34  $\mu\text{g/mL}$  and 68  $\mu\text{g/mL}$  resulting in significant  $6.2 \pm 0.6$  log and  $6.4 \pm 0.6$  log decreases in biofilm formation, respectively. These results clearly demonstrate the potent biofilm inhibiting activity of SPI009 for both Gram-negative and Gram-positive model pathogens.

To explore biofilm eradication, SPI009 was added to mature biofilms and survival was assessed after 5 h of treatment. For *P. aeruginosa* the lower concentrations (8.5 and 17  $\mu\text{g/mL}$ ) caused a decrease in biofilm survival of about 0.8 log units (Figure 3B). Doses of 34  $\mu\text{g/mL}$  or higher significantly decreased the number of surviving biofilms cells, resulting in  $4.2 \pm 0.6$ ;  $6.2 \pm 0.6$ ; and  $6.6 \pm 0.6$  log reductions. In comparison, 10  $\mu\text{g/mL}$  of the conventional antibiotic ofloxacin caused a significant  $4.5 \pm 1$  log decrease in the number of surviving biofilm cells (Supplementary Figure S2A). For *S. aureus*, the treatment of mature biofilms with lower concentrations of SPI009 proved slightly less effective than for *P. aeruginosa*. Treatment with higher concentrations did cause extensive damage, resulting in significant decreases in biofilm survival ranging between  $2.5 \pm 0.7$  and  $5.4 \pm 0.6$  log. For the 96-well biofilm models used in this study, the combination of SPI009 with a conventional antibiotic did not further decrease the number of surviving cells as compared to mono-treatment with SPI009 (Supplementary Figure S2). Overall, SPI009 shows potent activity in biofilms of both Gram-negative and Gram-positive species and is capable of significantly inhibiting biofilm formation and decreasing survival of mature biofilms.

## SPI009 Reduces Bacterial Load in a Chronic Wound Model


After confirming the biofilm eradication capacity of SPI009 in a standard biofilm set-up, a more clinically relevant model was used to assess the clinical potential of SPI009 as a topical antibacterial treatment. Using a porous cellulose matrix placed upon a moist hydrogel allowed the growth of a complex, three-dimensional hydrated structure, effectively mimicking biofilms in a chronic wound environment (Townsend et al., 2016; Kean et al., 2017). Assessment of viability was performed by means of live/dead quantitative PCR (Figure 4). For the viable cells, treatment with increasing concentrations of SPI009



alone resulted in significant  $1.6 \pm 0.5$  log (34  $\mu\text{g/mL}$ ) and  $2.0 \pm 0.5$  log (68  $\mu\text{g/mL}$ ) decreases in the number of surviving cells. The obtained results confirm the biofilm eradication capacity of SPI009, both as an antimicrobial and as part of a combination therapy, and this in a more complex, realistic biofilm environment.

## SPI009 Potentiates Antibiotic Activity in an Intracellular Infection Model

Next, the anti-persister and antibacterial activities of SPI009 were verified in a recently developed *P. aeruginosa* intracellular infection model (Buyck et al., 2013). Human THP-1 cells were infected with PAO1 cells (MOI 10) and treated for 5 h with different concentrations of ciprofloxacin, alone or in combination with 6.8 or 10.2  $\mu\text{g/mL}$  of SPI009. Concentrations of SPI009 were chosen to be well below the determined  $\text{IC}_{50}$  value of  $24.5 \pm 1.36$   $\mu\text{g/mL}$ . After treatment, both the number of surviving PAO1 cells and the amount of eukaryotic proteins present was assessed, as this can provide information about the possible toxic effect of the different treatments and the infecting bacteria. While treatment with SPI009 alone caused non-significant decreases of  $0.78 \pm 0.7$  and  $0.89 \pm 0.7$  log units in surviving bacteria, addition of SPI009 to ciprofloxacin greatly improved the antibacterial effect for all concentrations tested and this in a dose-dependent manner (Figure 5). Maximal antibacterial activity for the combination therapy with 10.2  $\mu\text{g/mL}$  of SPI009 occurs at ciprofloxacin concentrations of 10  $\mu\text{g/mL}$ , resulting in complete eradication of the bacterial culture. Moreover, all combinations tested significantly reduced the bacterial load as compared to ciprofloxacin alone. Combination treatment with 6.8  $\mu\text{g/mL}$  SPI009 showed a maximal  $0.78 \pm 0.6$  log decrease as compared




to antibiotic alone at a ciprofloxacin concentration of 20 µg/mL. These results clearly show that SPI009 can effectively penetrate the eukaryotic cell membrane, without causing extensive damage, to eradicate the intracellular *P. aeruginosa* infection.

### SPI009 Combination Therapy Significantly Improves *In Vivo* Survival

Since the antibacterial effect of SPI009 was demonstrated extensively *in vitro*, a next step was to assess the effect of this new compound in an *in vivo* *C. elegans* gut infection model. Toxicity testing of SPI009 in *C. elegans* revealed minor levels of toxicity at 68 µg/mL and >80% killing at 136 µg/mL (Supplementary Figure S3), excluding these concentrations from further experiments. Analysis of the different DMSO concentrations suggests that the observed toxicity is mainly caused by increasing concentrations of the solvent.

Infection of nematodes with PA14 resulted in 91.5% killing within 6 days after the start of infection, confirming the highly virulent nature of the PA14 strain in this model (Figure 6). Addition of 8.5 µg/mL of SPI009 alone slightly improved survival but not as good as 5x MIC of ciprofloxacin, resulting in survival rates of 19.0% ( $P = 0.045$ ) and 46.6% ( $P < 0.0001$ ), respectively. However, addition of 8.5 µg/mL of SPI009 to ciprofloxacin greatly increased survival, resulting in 73.8% nematode survival after 6 days. These results show a significant improvement in antibacterial effect of the combination therapy compared to the untreated ( $P < 0.0001$ ) and ciprofloxacin-treated ( $P = 0.0001$ ) controls (Supplementary Table S1). Since low doses of SPI009 can greatly enhance the effect of conventional antibiotic treatment, resulting in more than 73% survival, these results indicate the highly efficient antibacterial and potentiating effect of SPI009 as part of a combination therapy.



## DISCUSSION

Decades of excessive drug prescription, misuse of antimicrobials and extensive agricultural applications have caused a massive increase in drug resistance. Conventional antibiotic therapies are losing the battle against emerging extensively drug-resistant strains, resulting in 25,000 annual deaths in the European Union (European Centre for Disease Prevention and Control, 2009). A group of pathogens raising particular concern are the so-called ESKAPE pathogens, *E. faecium*, *S. aureus*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *Enterobacter* spp. Responsible for the majority of nosocomial infections, these pathogens show significant rises in resistance rates and are becoming increasingly difficult to treat with currently available antibiotics (Boucher et al., 2009; Pendleton et al., 2013). Since it is becoming alarmingly difficult to identify novel antibiotic targets, combination therapies could provide an alternative strategy for the effective treatment of bacterial infections. When different mode of actions are combined, they can lower the risk of resistance development and extend the life span of currently available antibiotics (Tamma et al., 2012; Gill et al., 2015). However, additional research is needed to assess possible negative effects associated with combination therapies and to determine an optimal combination *in vivo* (Tamma et al., 2012; Pena-Miller et al., 2013). An additional advantage of combination therapies is their potential use in the treatment of persister cells (Cui et al., 2016; Feng et al., 2016; Yang et al., 2016; Gallo et al., 2017; Koeva et al., 2017), a small reservoir of phenotypical variants that tolerate antibiotic treatment and reinstate bacterial infection when the antibiotic pressure drops. The antibiotic-tolerant phenotype of persister cells contributes to the recalcitrant nature of chronic infections,

greatly complicates treatment and increases the chances of resistance development (Lewis, 2007; Fauvart et al., 2011; Michiels et al., 2016).

We recently described the discovery of the propanol-amine derivative SPI009, a novel anti-persister molecule capable of directly killing persister cells of *P. aeruginosa* (Liebens et al., 2017). Most anti-persister molecules described in literature are only active against one or a very limited number of bacterial species, which can be explained by a very specific mode of action or the sensitizing of persister cells to a specific class of antibiotics (Wood, 2015; Van den Bergh et al., 2017). Other examples of small organic compounds capable of directly killing persister cells include the recently described  $\alpha$ -bromocinnamaldehyde (Shen et al., 2017), 5-iodoindole (Lee et al., 2016), halogenated phenazines (Garrison et al., 2015) and the nitroimidazole prodrug PA-284 (Singh et al., 2008). In this study, we showed that SPI009 possesses broad-spectrum activity and is capable of significantly decreasing or even eradicating the bacterial culture for all pathogens tested, including the notorious ESKAPE pathogens. In addition, combination therapy of conventional antibiotics with SPI009 allowed the efficient treatment of polymyxin B and ofloxacin resistant strains and could lower the required concentration of antibiotics, thereby enabling their use in resistant strains.

The close relationship between persisters and chronic infections (LaFleur et al., 2006; Mulcahy et al., 2010) is partly caused by their presence in biofilms. The presence of the biofilm matrix is capable of physically protecting the persister cells against the human immune system, thereby enabling the persister cells to resume growth when antibiotic pressure drops and cause recurrence of infection. When compared to other anti-biofilm compounds or conventional antibiotics, SPI009 monotherapy shows a promising anti-biofilm effect, both decreasing biofilm formation and causing a strong reduction in the number of surviving biofilm cells, for both Gram-negative and Gram-positive species. A more clinically relevant biofilm model was obtained by *P. aeruginosa* growth on cellulose matrices and hydrogels, providing a three-dimensional structure and moist environment closely mimicking the environment of a chronically infected wound. In this 3D model, clinical treatments have been shown to have less impact on the viability of biofilms in comparison to traditional 2D models, which are more susceptible to eradication (Townsend et al., 2016; Kean et al., 2017). Therefore this further supports the ability of SPI009 monotherapy to eradicate cells in a more complex biofilm model and suggests the possible use of SPI009 in the topical treatment of chronically infected wounds. For all biofilm experiments executed, the addition of SPI009 to a conventional antibiotic did not further decrease the biofilm population as compared to SPI009 alone. In comparison to planktonic cultures, where combination therapy with antibiotics strongly enhances the antibacterial effect, the specific lay-out and environment of the bacterial biofilm, including a possibly reduced penetration of antibacterials, could impair the cooperation between both antibacterials.

Besides the biofilm matrix, persister cells have also been shown to use eukaryotic cells to shield themselves from the human

immune system. The presence of intracellular persister reservoirs has been confirmed *in vivo* and can be associated with the chronic nature of infections (Buyck et al., 2013; Helaine et al., 2014). The ability of SPI009 to effectively reduce the intracellular bacteria further confirms the potential of SPI009 as an adjuvant in combination therapies. Capable of increasing nematode survival to more than 70% when combined with ciprofloxacin, the *in vivo* *C. elegans* model further contributes to the clinical potential of SPI009. The *C. elegans* model has been extensively used in the identification and clinical assessment of novel antibacterials and antifungals with ample studies confirming the consistent correlation between toxic effects in *C. elegans* and mammalian models (Hunt, 2017).

## CONCLUSION

We demonstrated that the anti-persister molecule SPI009 possesses a broad-spectrum antibacterial activity and, taken into account that it can be combined with different classes of antibiotics, shows great potential for the development of case-specific antibacterial combination therapies. The clinical potential of SPI009 was further confirmed by the observation of an excellent anti-biofilm activity, successful eradication of an intracellular infection in human eukaryotes and the significant increase in *C. elegans* survival after treatment with the combination of SPI009 and ciprofloxacin. Additional *in vivo* experiments will be required to assess the future applicability of SPI009 but its excellent activity in antibacterial combination therapies holds great promise.

## AUTHOR CONTRIBUTIONS

Conceptualization, VD, RC, AM, PC, MF, and JM. Methodology, VD, FVB, GR, MF, and JM. Formal analysis, VD. Investigation, VD, LV, AA, and EMT. Wrote the original draft, VD. Contributed in writing review and editing, VD, FVB, GR, MF, and JM. Visualization, VD. Supervision, MF and JM.

## FUNDING

This work was supported by Ph.D. grants of the Agency for Innovation through Science and Technology (IWT) to VD; the KU Leuven Excellence Center (grant number PF/2010/07), the KU Leuven Research Council (grant number PF/10/010, 'NATAR'); the Belgian Science Policy Office (BELSPO) (IAP P7/28) and the Fund for Scientific Research, Flanders (FWO) (grant numbers G047112N; G0B2515N; G055517N).

## ACKNOWLEDGMENTS

The authors thank Pierre Cornelis and Bob Hancock for providing us with the *P. aeruginosa* PA14 wild type

strain and *P. aeruginosa* clinical isolate 9BR. They would like to thank Prof. Liesbet Temmerman (Animal Physiology and Neurobiology, KU Leuven, Leuven, Belgium) and Francisco José Naranjo Galindo for introducing us to the *C. elegans* model.

## REFERENCES

- Arivett, B. A., Ream, D. C., Fiester, S. E., Mende, K., Murray, C. K., Thompson, M. G., et al. (2015). Draft genome sequences of *Klebsiella pneumoniae* clinical type strain ATCC 13883 and three multidrug-resistant clinical isolates. *Genome Announc.* 3:e01385-14. doi: 10.1128/genomeA.01385-14
- Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., et al. (2006). Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol. Syst. Biol.* 2:2006.0008. doi: 10.1038/msb4100050
- Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A. (2013). New antibiotics for bad bugs: where are we? *Ann. Clin. Microbiol. Antimicrob.* 12:22. doi: 10.1186/1476-0711-12-22
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESAP! An update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* 48, 1–12. doi: 10.1086/595011
- Boyle, B., Fernandez, L., Laroche, J., Kukavica-Ibrulj, I., Mendes, C. M. F., Hancock, R. E. W., et al. (2012). Complete genome sequences of three *Pseudomonas aeruginosa* isolates with phenotypes of polymyxin B adaptation and inducible resistance. *J. Bacteriol.* 194, 529–530. doi: 10.1128/JB.06246-11
- Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., et al. (2014). Engineered endolysin-based “Artilyns” to combat multidrug-resistant Gram-negative pathogens. *mBio* 5:e1379-14. doi: 10.1128/mBio.01379-14
- Buyck, J. M., Tulkens, P. M., and Van Bambeke, F. (2013). Pharmacodynamic evaluation of the intracellular activity of antibiotics towards *Pseudomonas aeruginosa* PAO1 in a model of THP-1 human monocytes. *Antimicrob. Agents Chemother.* 57, 2310–2318. doi: 10.1128/AAC.02609-12
- Cohen, N. R., Lobritz, M. A., and Collins, J. J. (2013). Microbial persistence and the road to drug resistance. *Cell Host Microbe* 13, 632–642. doi: 10.1016/j.chom.2013.05.009
- Conlon, B. P., Nakayasu, E. S., Fleck, L. E., LaFleur, M. D., Isabella, V. M., Coleman, K., et al. (2013). Activated ClpP kills persisters and eradicates a chronic biofilm infection. *Nature* 503, 365–370. doi: 10.1038/nature12790
- Cui, P., Niu, H., Shi, W., Zhang, S., Zhang, H., Margolick, J., et al. (2016). Disruption of membrane by colistin kills uropathogenic *Escherichia coli* persisters and enhances killing of other antibiotics. *Antimicrob. Agents Chemother.* 60, 6867–6871. doi: 10.1128/AAC.01481-16
- Descheemaeker, P., Lammens, C., Pot, B., Vandamme, P., and Goossens, H. (1997). Evaluation of arbitrarily primed PCR analysis and pulsed-field gel electrophoresis of large genomic DNA fragments for identification of enterococci important in human medicine. *Int. J. Syst. Bacteriol.* 47, 555–561. doi: 10.1099/00207713-47-2-555
- European Centre for Disease Prevention and Control (2009). *The Bacterial Challenge: Time to React*. Stockholm: ECDC. doi: 10.2900/2518
- European Centre for Disease Prevention and Control (2013). *Point Prevalence Survey of Healthcare-associated Infections and Antimicrobial Use in European Acute Care Hospitals 2011–2012*. Stockholm: ECDC.
- European Committee on Antimicrobial Susceptibility Testing (2017). *Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 7.1, 2017*. Available at: <http://www.eucast.org>
- Fauvart, M., De Groote, V. N., and Michiels, J. (2011). Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. *J. Med. Microbiol.* 60, 699–709. doi: 10.1099/jmm.0.030932-0
- Feng, J., Shi, W., Zhang, S., Sullivan, D., Auwaerter, P. G., and Zhang, Y. (2016). A drug combination screen identifies drugs active against amoxicillin-induced round bodies of *in vitro* *Borrelia burgdorferi* persisters from an FDA drug library. *Front. Microbiol.* 7:743. doi: 10.3389/fmicb.2016.00743
- Fischbach, M. A., and Walsh, C. T. (2009). Antibiotics for emerging pathogens. *Science* 325, 1089–1093. doi: 10.1126/science.1176667
- Gallo, S. W., Ferreira, C. A. S., and de Oliveira, S. D. (2017). Combination of polymyxin B and meropenem eradicates persister cells from *Acinetobacter baumannii* strains in exponential growth. *J. Med. Microbiol.* 66, 57–60. doi: 10.1099/jmm.0.000542
- Garrison, A. T., Abouelhasan, Y., Kallifidas, D., Bai, F., Ukhanova, M., Mai, V., et al. (2015). Halogenated phenazines that potently eradicate biofilms, MRSA persister cells in non-biofilm cultures, and *Mycobacterium tuberculosis*. *Angew. Chem. Int. Ed.* 54, 14819–14823. doi: 10.1002/anie.201508155
- Gill, E. E., Franco, O. L., and Hancock, R. E. W. (2015). Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. *Chem. Biol. Drug Des.* 85, 56–78. doi: 10.1111/cbdd.12478
- Helaine, S., Cheverton, A. M., Watson, K. G., Faure, L. M., Matthews, S., and Holden, D. W. (2014). Internalization of *Salmonella* by macrophages induces formation of nonreplicating persisters. *Science* 343, 204–208. doi: 10.1126/science.1244705
- Hermans, K., Nguyen, T. L. A., Roberfroid, S., Schoofs, G., Verhoeven, T., De Coster, D., et al. (2011). Gene expression analysis of monospecies *Salmonella* Typhimurium biofilms using differential fluorescence induction. *J. Microbiol. Methods* 84, 467–478. doi: 10.1016/j.mimet.2011.01.012
- Hunt, P. R. (2017). The *C. elegans* model in toxicity testing. *J. Appl. Toxicol.* 37, 50–59. doi: 10.1002/jat.3357
- Kean, R., Rajendran, R., Haggarty, J., Townsend, E. M., Short, B., Burgess, K. E., et al. (2017). *Candida albicans* mycofilms support *Staphylococcus aureus* colonization and enhances miconazole resistance in dual-species interactions. *Front. Microbiol.* 8:258. doi: 10.3389/fmicb.2017.00258
- Koeva, M., Gutu, A. D., Hebert, W., Wager, J. D., Yonker, L. M., O'Toole, G. A., et al. (2017). An anti-persister strategy for the treatment of chronic *Pseudomonas aeruginosa* infections. *Antimicrob. Agents Chemother.* 16:S12. doi: 10.1128/AAC.00987-17
- LaFleur, M. D., Kumamoto, C. A., and Lewis, K. (2006). *Candida albicans* biofilms produce antifungal-tolerant persister cells. *Antimicrob. Agents Chemother.* 50, 3839–3846. doi: 10.1128/AAC.00684-06
- Lee, D. G., Urbach, J. M., Wu, G., Liberati, N. T., Feinbaum, R. L., Miyata, S., et al. (2006). Genomic analysis reveals that *Pseudomonas aeruginosa* virulence is combinatorial. *Genome Biol.* 7:R90. doi: 10.1186/gb-2006-7-10-r90
- Lee, J.-H., Kim, Y.-G., Gwon, G., Wood, T. K., and Lee, J. (2016). Halogenated indoles eradicate bacterial persister cells and biofilms. *AMB Express* 6:123. doi: 10.1186/s13568-016-0297-6
- Lewis, K. (2007). Persister cells, dormancy and infectious disease. *Nat. Rev. Microbiol.* 5, 48–56. doi: 10.1038/nrmicro1557
- Liebens, V., Defraigne, V., Knapen, W., Swings, T., Beullens, S., Corbau, R., et al. (2017). Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a novel antibacterial compound active against persisters of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 61:e00836-17. doi: 10.1128/AAC.00836-17
- Livermore, D. M. (2004). The need for new antibiotics. *Clin. Microbiol. Infect.* 10, 1–9. doi: 10.1111/j.1465-0691.2004.1004.x
- Merabishvili, M., Vandenheuvel, D., Kropinski, A. M., Mast, J., De Vos, D., Verbeken, G., et al. (2014). Characterization of newly isolated lytic bacteriophages active against *Acinetobacter baumannii*. *PLOS ONE* 9:e104853. doi: 10.1371/journal.pone.0104853
- Michiels, J. E., Van den Bergh, B., Verstraeten, N., and Michiels, J. (2016). Molecular mechanisms and clinical implications of bacterial persistence. *Drug Resist. Updat.* 29, 76–89. doi: 10.1016/j.drug.2016.10.002
- Mulcahy, L. R., Burns, J. L., Lory, S., and Lewis, K. (2010). Emergence of *Pseudomonas aeruginosa* strains producing high levels of persister cells in patients with cystic fibrosis. *J. Bacteriol.* 192, 6191–6199. doi: 10.1128/JB.01651-09

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2017.02585/full#supplementary-material>

- O'Neill, J. (2016). *Tackling Drug-resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance*. London: HM Government.
- Pena-Miller, R., Laehnemann, D., Jansen, G., Fuentes-Hernandez, A., Rosenstiel, P., Schulenburg, H., et al. (2013). When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. *PLOS Biol.* 11:e1001540. doi: 10.1371/journal.pbio.1001540
- Pendleton, J. N., Gorman, S. P., and Gilmore, B. F. (2013). Clinical relevance of the ESKAPE pathogens. *Expert Rev. Anti Infect. Ther.* 11, 297–308. doi: 10.1586/eri.13.12
- Porta-de-la-Riva, M., Fontrodona, L., Villanueva, A., and Cerón, J. (2012). Basic *Caenorhabditis elegans* methods: synchronization and observation. *J. Vis. Exp.* 64:e4019. doi: 10.3791/4019
- Rice, L. B. (2008). Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J. Infect. Dis.* 197, 1079–1081. doi: 10.1086/533452
- Shen, Q., Zhou, W., Hu, L., Qi, Y., Ning, H., Chen, J., et al. (2017). Bactericidal activity of alpha-bromocinnamaldehyde against persisters in *Escherichia coli*. *PLOS ONE* 12:e0182122. doi: 10.1371/journal.pone.0182122
- Shin, S. H., Kim, S., Kim, J. Y., Lee, S., Um, Y., Oh, M.-K., et al. (2012). Complete genome sequence of *Enterobacter aerogenes* KCTC 2190. *J. Bacteriol.* 194, 2373–2374. doi: 10.1128/JB.00028-12
- Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., et al. (2008). PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release. *Science* 322, 1392–1395. doi: 10.1126/science.1164571
- Smith, K., Collier, A., Townsend, E. M., O'Donnell, L. E., Bal, A. M., Butcher, J., et al. (2016). One step closer to understanding the role of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers. *BMC Microbiol.* 16:54. doi: 10.1186/s12866-016-0665-z
- Stiernagle, T. (2006). *Maintenance of C. elegans*. Available at: <http://www.wormbook.org>
- Tamma, P. D., Cosgrove, S. E., and Maragakis, L. L. (2012). Combination therapy for treatment of infections with Gram-negative bacteria. *Clin. Microbiol. Rev.* 25, 450–470. doi: 10.1128/CMR.05041-11
- Townsend, E. M., Sherry, L., Rajendran, R., Hansom, D., Butcher, J., Mackay, W. G., et al. (2016). Development and characterisation of a novel three-dimensional inter-kingdom wound biofilm model. *Biofouling* 32, 1259–1270. doi: 10.1080/08927014.2016.1252337
- Van Acker, H., Sass, A., Bazzini, S., De Roy, K., Udine, C., Messiaen, T., et al. (2013). Biofilm-grown *Burkholderia cepacia* complex cells survive antibiotic treatment by avoiding production of reactive oxygen species. *PLOS ONE* 8:e58943. doi: 10.1371/journal.pone.0058943
- Van den Bergh, B., Fauvart, M., and Michiels, J. (2017). Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. *FEMS Microbiol. Rev.* 41, 219–251. doi: 10.1093/femsre/fix001
- WHO (2017). *Global Priority List of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics*. Geneva: WHO.
- Wood, T. K. (2015). Combatting bacterial persister cells. *Biotechnol. Bioeng.* 113, 476–483. doi: 10.1002/bit.25721
- Yang, S., Hay, I. D., Cameron, D. R., Speir, M., Cui, B., Su, F., et al. (2016). Antibiotic regimen based on population analysis of residing persister cells eradicates *Staphylococcus epidermidis* biofilms. *Sci. Rep.* 5:18578. doi: 10.1038/srep18578

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Defraigne, Verstraete, Van Bambeke, Anantharajah, Townsend, Ramage, Corbau, Marchand, Chaltin, Fauvart and Michiels. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## Supplementary Material


### Antibacterial activity of 1-((2,4-dichlorophenethyl)amino)-3-phenoxypropan-2-ol against antibiotic-resistant strains of diverse bacterial pathogens, biofilms and in pre-clinical infection models

Valerie Defraigne, Laure Verstraete, Françoise Van Bambeke, Ahalieyah Anantharajah, Eleanor M. Townsend, Gordon Ramage, Romu Corbau, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels


\* **Correspondence:** corresponding author: jan.michiels@kuleuven.vib.be

#### 1 Supplementary Data


##### 1.1 Supplementary Figures



**Figure S1: Determination of the persister plateau.** Stationary phase cultures of (A) *E. aerogenes* (open circle), *K. pneumoniae* (open square), *A. baumannii* (open triangle), *P. aeruginosa* (filled triangle), *E. coli* (open diamond) and (B) *S. aureus* (open circle), *E. faecium* (open square) and *B. cenocepacia* (open triangle) were treated for 5 hours with increasing concentrations of (A) ofloxacin or (B) rifampicin (RIF) or ciprofloxacin (CIP). Data points represent the means of three independent experiments, with error bars depicting the SEM value.



**Figure S2: Effect of conventional antibiotics in the treatment of bacterial biofilms.** 24 hour, mature biofilms of (A) *P. aeruginosa* and (B) *S. aureus* were treated for 5 hours with a conventional antibiotic, ofloxacin (OFX) and vancomycin (VAN) respectively, or the combination of this antibiotic with increasing concentrations of SPI009. Assessment of biofilm survival was done by CFU counting and statistical differences to the control treatment were detected by means of a one-way ANOVA ( $\alpha=0.05$ ) with Dunnett's correction for multiple comparisons. Data points represent the average of three independent repeats, each containing three technical repeats,  $\pm$  SEM with \*\*  $P < 0.01$  and \*\*\*  $P < 0.001$ . No significant decreases in biofilm survival were observed for the combination therapy, as compared to treatment with equal concentrations of SPI009 alone.



**Figure S3: Toxicity testing of SPI009 in *C. elegans*.** OP50 fed nematodes were monitored for 5 days in the presence of increasing concentrations of SPI009 (8.5-134  $\mu\text{g}/\text{mL}$ ). Controls consisted of untreated worms (negative control, black line), 2% DMSO (carrier control, red solid line) and 20% DMSO (positive control, red dotted line). Data point represent the average of at least two independent experiments, as determined by means of Kaplan-Meier survival plots. Statistical analysis was done

using log-rank test which showed significant differences between the untreated control and 68 µg/mL, 136 µg/mL, 2% DMSO and 20% DMSO. No toxicity was observed for SPI009 concentrations of 8.5 µg/mL ( $P = 0.359$ ), 17 µg/mL ( $P = 0.556$ ) and 34 µg/mL ( $P = 0.094$ ).

## 1.2 Supplementary tables

**Table S1: Statistical analysis of *C. elegans* survival data.** The Kaplan-Meier method was used to analyze the obtained survival data. N represents the total number of subjects, median lifespan is considered >6 if, at the end of the experiment > 50% of the population is still alive. Kaplan-Meier curves (Figure 6) were statistically analyzed using a log-rank test to compare between treatments and control or different treatments, as indicated in the table.  $P_{\text{log-rank}}$  indicates the P-value as a result of the log-rank analysis ( $\alpha = 0.05$ ), the last column indicates significance levels after the Bonferroni correction for multiple comparisons ( $\alpha = 0.01$ ).

| Group                     | N   | median lifespan<br>(days) | $P_{\text{log-rank}}$       | Bonferroni<br>correction |
|---------------------------|-----|---------------------------|-----------------------------|--------------------------|
| un-infected               | 351 | >6                        |                             |                          |
| untreated                 | 165 | 4                         | < 0.0001 vs un-<br>infected | ****                     |
| 8.5 µg/mL SPI009          | 85  | 4                         | 0.0452 vs untreated         | ns                       |
| CIP (5 x MIC)             | 132 | 6                         | < 0.0001 vs untreated       | ****                     |
| CIP + 8.5 µg/mL<br>SPI009 | 81  | >6                        | < 0.0001 vs untreated       | ****                     |
|                           |     |                           | 0.0001 vs CIP               | ****                     |